Chemotherapy‑induced complications in patients with lung cancer: An evaluation by pharmacists

Ishikawa,Asuka; Ohara,Gen; Nakazawa,Kensuke; Tamura,Tomohiro; Sato,Shinya; Kagohashi,Katsunori; Kurishima,Koichi; Ito,Yoko; Satoh,Hiroaki

doi:10.3892/mco.2012.33

Chemotherapy‑induced complications in patients with lung cancer: An evaluation by pharmacists

Authors:
- Asuka Ishikawa
- Gen Ohara
- Kensuke Nakazawa
- Tomohiro Tamura
- Shinya Sato
- Katsunori Kagohashi
- Koichi Kurishima
- Yoko Ito
- Hiroaki Satoh
View Affiliations

Affiliations: Division of Pharmacy, Mito Kyodo General Hospital, Mito Medical Center, University of Tsukuba, Mito, Ibaraki 310-0015, Japan, Division of Respiratory Medicine, Mito Medical Center, University of Tsukuba, Mito, Ibaraki 310-0015, Japan
Published online on: October 2, 2012 https://doi.org/10.3892/mco.2012.33
Pages: 65-68

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In lung cancer patients, chemotherapy‑induced complications are considered to be distressing reactions even in the era of new antiemetics, such as aprepitant. The aim of this study was to evaluate the incidence of such complications. This prospective observational study was performed in our institution between 2011 and 2012. Certain complications including nausea, vomiting, appetite, stomatitis, constipation, diarrhea and dysesthesia, on days 1‑7 were evaluated by pharmacists. The questionnaires and diaries of chemotherapy‑induced complications were evaluated in the 31 patients included in the study. The majority of the enrolled patients were male (81%). Six (19%) patients were administered cis-diamminedichloroplatinum(II) (CDDP)‑, 21 (69%) chemotherapy by carboplatin (CBDCA)‑ and 4 (13%) non‑platinum regimen chemotherapies. Ten (32.3%) of the 31 patients exhibited nausea but only 3 (9.7%) of them experienced vomiting. On days 5-6, 23.8 and 9.5%, respectively, of patients treated with CDDP‑regimens had nausea and vomiting. Three of the other most common complications were constipation, general fatigue and appetite loss. The incidence of these complications was 77.4, 71.0 and 67.7%, respectively. Even in the era of new antiemetics, CDDP‑regimen chemotherapy-induced nausea and vomiting as well as constipation; general fatigue and appetite loss continue to be problems. A better appreciation of the incidence of these chemotherapy-related complications by medical oncologists and medical staff is essential for their adequate control.

View Figures

View References

1.	Peters BG: An overview of chemotherapy toxicities. Top Hosp Pharm Manage. 14:59–88. 1994.
2.	Van Ryckeghem F and Van Belle S: Management of chemotherapy-induced nausea and vomiting. Acta Clin Belg. 65:305–310. 2010.
3.	Grunberg SM and Hesketh PJ: Control of chemotherapy-induced emesis. N Engl J Med. 329:1790–1796. 1993.
4.	Hickok JT, Roscoe JA, Morrow GR, King DK, Atkins JN and Fitch TR: Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: a University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treated in the community. Cancer. 97:2880–2886. 2003.
5.	Hesketh PJ, Grunberg SM, Gralla RJ, et al: Aprepitant Protocol 052 Study Group: The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - the Aprepitant Protocol 052 Study Group. J Clin Oncol. 21:4112–4119. 2003.
6.	Warr DG, Grunberg SM, Gralla RJ, et al: The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: pooled data from 2 randomised, double-blind, placebo controlled trials. Eur J Cancer. 41:1278–1285. 2005.
7.	Warr DG, Hesketh PJ, Gralla RJ, et al: Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol. 23:2822–2830. 2005.
8.	Osoba D: Health-related quality-of-life assessment in clinical trials of supportive care in oncology. Support Care Cancer. 8:84–88. 2000.
9.	Barford KL and D’Olimpio JT: Symptom management in geriatric oncology: practical treatment considerations and current challenges. Curr Treat Options Oncol. 9:204–214. 2008.
10.	Stokman MA, Spijkervet FK, Boezen HM, Schouten JP, Roodenburg JL and de Vries EG: Preventive intervention possibilities in radiotherapy- and chemotherapy-induced oral mucositis: results of meta-analyses. J Dent Res. 85:690–700. 2006.
11.	Park SB, Krishnan AV, Lin CS, Goldstein D, Friedlander M and Kiernan MC: Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies. Curr Med Chem. 15:3081–3094. 2008.
12.	Navari RM, Reinhardt RR, Gralla RJ, et al: Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754, 030 Antiemetic Trials Group. N Engl J Med. 340:190–195. 1999.
13.	Coates A, Abraham S, Kaye SB, et al: On the receiving end-patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol. 19:203–208. 1983.
14.	Griffin AM, Butow PN, Coates AS, et al: On the receiving end. V: patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol. 7:189–195. 1986.
15.	Erazo Valle A, Wisniewski T, Figueroa Vadillo JI, Burke TA and Martinez Corona R: Incidence of chemotherapy-induced nausea and vomiting in Mexico: healthcare provider predictions versus observed. Curr Med Res Opin. 22:2403–2410. 2006.
16.	Grunberg SM, Deuson RR, Mavros P, et al: Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer. 100:2261–2268. 2004.
17.	Liau CT, Chu NM, Liu HE, Deuson R, Lien J and Chen JS: Incidence of chemotherapy-induced nausea and vomiting in Taiwan: physicians’ and nurses’ estimation vs. patients’ reported outcomes. Support Care Cancer. 13:277–286. 2005.
18.	Majem M, Moreno ME, Calvo N, et al: Perception of healthcare providers versus patient reported incidence of chemotherapy-induced nausea and vomiting after the addition of NK-1 receptor antagonists. Support Care Cancer. 19:1983–1990. 2011.
19.	Hilarius DL, Kloeg PH, van der Wall E, van den Heuvel JJ, Gundy CM and Aaronson NK: Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study. Support Care Cancer. 20:107–117. 2012.
20.	Yada T, Kohno D, Maejima Y, et al: Neurohormones, rikkunshito and hypothalamic neurons interactively control appetite and anorexia. Curr Pharm Des. May 23–2012.(Epub ahead of print).
21.	Takeda H, Sadakane C, Hattori T, et al: Rikkunshito, an herbal medicine, suppresses cisplatin-induced anorexia in rats via 5-HT2 receptor antagonism. Gastroenterology. 134:2004–2013. 2008.
22.	Takeda H, Muto S, Nakagawa K, Ohnishi S and Asaka M: Rikkunshito and ghrelin secretion. Curr Pharm Des. May 23–2012.(Epub ahead of print).
23.	Cheng KC, Li YX and Cheng JT: The use of herbal medicine in cancer-related anorexia/cachexia treatment around the world. Curr Pharm Des. May 23–2012.(Epub ahead of print).